

24
(12) UK Patent Application (19) GB (11) 2 163 747 A


(43) Application published 5 Mar 1986

(21) Application No 8521493	(51) INT CL ⁴ C07D 235/28 A61K 31/415 31/445 C07D 401/12 // (C07D 401/12 235:28 295:08)
(22) Date of filing 29 Aug 1985	
(30) Priority data (31) 59/182400 (32) 31 Aug 1984 (33) JP 60/061194 26 Mar 1985 60/061195 26 Mar 1985	(52) Domestic classification C2C 1416 1532 213 215 220 221 225 226 22Y 246 250 251 252 25Y 28X 30Y 311 313 31Y 321 322 323 32Y 337 338 364 366 368 36Y 397 462 551 614 620 630 660 670 680 694 697 699 802 80Y AA QL RL RM U1S 1318 C2C
(71) Applicant Nippon Chemiphar Co Ltd (Japan), 2-2-3 Iwamoto-cho, Chiyoda-ku, Tokyo, Japan	(56) Documents cited None
(72) Inventor Susumu Okabe Masaru Satoh Tomio Yamakawa Yutaka Nomura Masatoshi Hayashi	(58) Field of search C2C
(74) Agent and/or Address for Service G F Redfern & Co, Marlborough Lodge, 14 Farncombe Road, Worthing, West Sussex BN11 2BT	

Reprinted front page

(54) Benzimidazole derivatives

(57) Benzimidazole derivatives of the formula



(where R₁ is hydrogen, C₁₋₈ alkyl, cycloalkyl, phenyl or aralkyl, R₂ is hydrogen or C₁₋₈ alkyl, or R₁ and R₂ together form a ring with the adjacent nitrogen atom, and R₃ and R₄ are hydrogen, halogen, trifluoromethyl, alkyl, alkoxy, alkoxy carbonyl or amino) are antiulcer agents.

GB 2 163 747 A

SPECIFICATION

Benzimidazole derivatives, process for preparing the same and antiulcer agents containing the same

5 This invention relates to novel benzimidazole derivatives, to a process for preparing such derivatives and to antiulcer agents containing such derivatives.

As is well known in the art to which the present invention relates, $H^+ + K^+$ -ATPase plays a principal role in the final secretion mechanism of gastric acid in stomach cells [Scand. J. 10 Gastroenterol., 14, 131-135 (1979)]. Norinium bromide is known as a substance having $H^+ + K^+$ -ATPase inhibitory activity [Proceeding of the Society for Experimental Biology and Medicine, 172, 308-315 (1983)].

15 On the other hand, 2-[2-(3,5-dimethyl-4-methoxy)pyridylmethylsulfinyl]-5-methoxy-benzimidazole [Omeprazole] has been developed as an antiulcer compound having $H^+ + K^+$ -ATPase inhibitory activity [Am. J. of Physiol., 245, G64-71 (1983)].

15 There is a keen demand for new compounds having a more enhanced effect on $H^+ + K^+$ -ATPase inhibition than these known compounds.

20 With the foregoing in view, the present Applicants have conducted extensive research and have now found that certain benzimidazole derivatives exhibit excellent suppressive effects 20 against the secretion of gastric acid owing to their specific $H^+ + K^+$ -ATPase inhibitory effects, coupled with cytoprotective action.

It is an object of the present invention, therefore, to provide new benzimidazole derivatives which are useful for antiulcer purposes.

25 Another object of the invention is to provide a novel process for preparing such benzimidazole derivatives.

Still another object of the invention is to provide antiulcer agents containing such benzimidazole derivatives as an effective component thereof.

According to a first aspect of the present invention, there is provided benzimidazole derivatives represented by the formula (I),



where R_1 is a hydrogen atom, or an alkyl group of 1 to 8 carbon atoms, or a cycloalkyl, phenyl or aralkyl group; R_2 is a hydrogen atom, or an alkyl group of 1 to 8 carbon atoms; or R_1 and R_2 together form a ring with the adjacent nitrogen atom; and R_3 and R_4 are in each case a hydrogen or halogen atom, or a trifluoromethyl, lower alkyl, lower alkoxy, lower alkoxy carbonyl or amino group, and may be the same or different.


According to a second aspect of the invention there is provided a process for preparing a benzimidazole derivative as specified above, which comprises reacting a 2-mercaptopbenzimidazole 45 represented by the formula (II),



where R_3 is as defined above, with a 2-aminobenzyl compound represented by the formula (III),






where R_1 , R_2 and R_4 are as defined above and X is a reactive group, thereby forming a compound represented by the formula (IV),



10 where R_1 , R_2 , R_3 and R_4 are as defined above, and then oxidizing the compound of the formula (IV). 10

According to a third aspect of the invention, there is provided an antiulcer agent comprising as an effective component thereof, a benzimidazole derivative as specified above.

15 Benzimidazole derivatives of the formula (I) according to the present invention may be prepared, for example, by reacting a 2-mercaptopbenzimidazole of the formula (II) with a 2-aminobenzyl compound of the formula (III) to form a compound of the formula (IV) and then oxidizing the compound (IV) in accordance with the following reaction scheme:-



where X is a reactive group and R₁ to R₄ inclusive are as defined previously.

50 The starting compound (III) useful for a process according to the invention is already known in the art. The compound (III) may be prepared, for example, by the process described in Org. Synth., 30, 56. The reactive group X in the other starting compound (III) may be a halogen atom, such as chlorine or bromine, or a sulfonyloxy group such as a methylsulfonyloxy or toluenesulfonyloxy group. The compound (III) in which a chlorine atom is bonded as X may be prepared, for example, by the process disclosed in J. Chem. Soc., 98-102 (1942). Both of these starting compounds can also be in the form of salts. 50
55

The reaction between the compound (II) and the compound (III), or between their respective salts, may be effected by stirring them in an inert solvent, such as toluene, benzene, ethanol or acetone, at a temperature of from room temperature to the refluxing temperature, for 30 minutes to 24 hours. In such case, it is preferred to have an alkaline compound such as NaOH, KOH, K_2CO_3 or $NaHCO_3$ present in the reaction system, so that the resulting acid can be neutralised.


The compound (IV) may be converted to its corresponding oxo compound by any method known *per se*. For example, this conversion may be achieved by oxidizing the compound (IV) with an oxidizing agent, for example, an organic peracid such as *m*-chloroperbenzoic acid, hydrogen peroxide, sodium hypochlorite or sodium metaperiodate. The reaction may be effected

in an inert solvent such as chloroform, dichloromethane, methanol or ethyl acetate, at -30 to +50°C, preferably at -15 to +5°C.

The pharmacological effects of some compounds typical of the invention were tested. The test results are given below.

5 (1) $H^{++}K^{+}$ ATPase inhibitory effects: 5

Following the method of Forte et al [J. Applied Physiol., 32, 714-717 (1972)], gastric acid secretory cells of a rabbit gastric mucosa were isolated and vesicle containing $H^{++}K^{+}$ ATPase was prepared by centrifuging the cells in Ficoll of discontinuous density gradient. After the 10 enzyme was incubated at room temperature for 25 minutes in 0.5 ml of a solution which contained 5 mM of an imidazole buffer (pH 6.0) and 2×10^{-4} M of each test compound, the mixture was heated to 37°C at which it was allowed to stand for further 5 minutes. To the 15 mixture was added 0.5 ml of a solution which contained 4 mM of magnesium chloride, 80 mM of an imidazole buffer (pH 7.4), 20 mM of potassium chloride and 4 mM of ATP. The resulting mixture was reacted at 37°C for 15 minutes and 1 ml of a 24% solution of trichloroacetic acid was then added to terminate the reaction. The inorganic phosphorus liberated was quantitatively 15 analyzed by the method proposed by Taussky and Shorr [J. Biol. Chem., 202, 675-685 (1953)]. The K^{+} -dependent activity of the ATPase was determined by subtracting its activity obtained when no potassium chloride was contained. The results are summarized in Table 1 in which 20 Inventive compounds 1 to 19 are the compounds obtained in several of Examples 1 to 26 and Comparative compound 1 is the compound obtained in Reference Example 1, all of which examples are set out below.

Table 1

Test compound	R	R ₃	R ₄	H ⁺ +K ⁺ ATPase Inhibitory effect (%)
Comparative compound 1	H	H	H	0
Inventive compound 1	NH ₂	H	H	88.2
Inventive compound 2	NHCH ₃	H	H	100
Inventive compound 3	N(CH ₃) ₂	H	H	100
Inventive compound 4	N(CH ₃) ₂	5-OCH ₃	H	100
Inventive compound 5	N(CH ₃) ₂	5-COOCH ₃	H	97.9
Inventive compound 6	N(CH ₃) ₂	5-CH ₃	H	100
Inventive compound 7	N(CH ₃) ₂	5-Cl	H	100
Inventive compound 8	N(CH ₃) ₂	5-CF ₃	H	100

Table 1 (cont'd)

Test compound	R	R ₃	R ₄	H ⁺ -K ⁺ ATPase Inhibitory effect (%)
Inventive compound 9	N(CH ₃) ₂	4-CH ₃	H	100
Inventive compound 10	N(CH ₃) ₂	H	6-CH ₃	100
Inventive compound 11	N(CH ₃) ₂	H	4-Cl	100
Inventive compound 12	N(CH ₃) ₂	H	5-OC ₂ H ₅	100
Inventive compound 13	N(CH ₃) ₂	H	5-CH ₃	100
Inventive compound 14	-N()	H	H	82.3
Inventive compound 15	-NH()	H	H	100
Inventive compound 16	-NH()	H	H	100
Inventive compound 17	-N() CH ₃	H	H	66.7
Inventive compound 18	-N() CH ₃	H	H	77.9
Inventive compound 19	-N() CH ₃	H	H	100

(2) Inhibitory effects against the secretion of gastric acid:

Male Donryu rats were used which had a body weight of 200 to 250 g and fasted (while allowing free access to water) for 24 hours in accordance with the usual method [Shay, H. et al, Gastroenterology, 5, 43-61 (1945)]. Under ether anesthesia the pylorus was ligated and each

5 test compound was administered intraduodenally. Four hours later, each rat was killed and the stomach was removed to collect the gastric juice. The inhibitory effect was determined by comparing the acid output which was obtained by titration to pH 7.0 with 0.1-N NaOH by means of an automatic titrator, with the corresponding value of a control rat prepared in the same manner except that a vehicle alone was administered. The results are given in Table 2.

10

5

10

Table 2

15	Test compound	Dose (mg/kg)	Suppressive effect against secretion of gastric acid (%)	15
20	Comparative compound 1	100	44	20
25	Cimetidine	100	80.3	25
		30	59.1	30
		10	25.3	35
30	Inventive compound 3	100	99.3	40
		30	94.3	45
		10	62.9	50
35	Inventive compound 7	100	77.5	55
40	Inventive compound 9	100	95.7	
45	Inventive compound 10	100	98.7	
50	Inventive compound 11	100	72.8	
55	Inventive compound 13	100	97.9	
	Inventive compound 15	100	91.5	
		30	71.7	
		10	48.8	

(3) Inhibitory effects against four gastric lesion models:

Four different types of gastric lesion models were induced in male Donryu rats (180 to 240 g) which had been deprived of food but allowed free access to water for 24 to 48 hours prior to experiments.

5

5

a) Shay ulcers:

Under ether anesthesia the abdomen of each rat fasted for 48 hours was incised and the pylorus ligated. Fourteen hours later, the animal was killed and the stomach was examined for any ulcer in the forestomach. Each test compound or a vehicle alone was given intraduodenally 10 in a volume of 0.2 ml/100 g body weight immediately after pylorus ligation.

10

b) Water-immersion stress-induced erosions:

Rats fasted for 24 hours before experiments were placed in a restraint cage. The animals were immersed vertically to the level of the xiphoid process in a water bath (21°C) for 7 hours and 15 then killed. The stomach of each rat was removed and inflated by injecting 10 ml of 1% formalin to fix the inner and outer layers of the gastric walls. This formalin treatment was performed in all of the following experiments. Subsequently, the stomach was incised along a greater curvature and examined for any erosion in the glandular portion. Each test compound or a vehicle alone was given orally 10 minutes before stressing.

15

20

20

c) Indomethacin-induced erosions:

Indomethacin suspended in a 0.2% CMC solution was given subcutaneously to rats in a dose of 25 mg/kg, which rats had been fasted for 24 hours before experiments. Seven hours later, each animal was killed and the stomach was examined for any erosion in the glandular portion.

25 Each test compound or a vehicle alone was given orally 10 minutes before indomethacin treatment.

25

d) HCl-EtOH-induced erosions:

A hydrochloric acid-ethanol solution (150 mM HCl in 60% EtOH) was given orally to rats in a dose of 1 ml/200 g, which rats had been fasted for 24 hours before experiments. One hour later, each animal was killed and the stomach was examined for any erosion in the glandular portion. Each test compound or a vehicle alone was given orally 30 minutes before ethanol treatment.

30

The results are shown in Table 3-A to Table 3-D.

Table 3-A

a) Shay ulcers

5	Test compound	mg/kg id	Inhibition (%)	5
10	Inventive compound 3	3	28	10
		10	68	
		30	69	
15	Cimetidine	100	-29	15
		300	44	

Table 3-B

b) Water-immersion stress-induced erosions

25	Test compound	mg/kg po	Inhibition (%)	25
30	Inventive compound 3	30	69	30
		100	97	
35	" 4	30	27	35
		100	95	
40	" 10	30	39	40
		100	91	
45	" 12	30	41	45
		100	74	
50	" 13	30	64	50
		100	88	
50	Cimetidine	60	49	50
		200	87	

Table 3-C

c) Indomethacin-induced erosions

Test compound	mg/kg po	Inhibition (%)
Inventive compound 3	30	7.0
	100	88
Cimetidine	30	39
	100	76

Table 3-D

d) HCl-EtOH-induced erosions

Test compound	mg/kg po	Inhibition (%)
Inventive compound 3	10	89
	30	100

(4) Acute toxicity test:

To male Wistar rats having a body weight of 80 to 90 g were intraperitoneally administered suspensions of certain inventive compounds which had been suspended in 0.2% CMC physiological saline. The rats were observed for 7 days. The results are shown in Table 4.

Table 4

Inventive compound	LD ₅₀
10	600 mg/kg or more
12	500 - 600 mg/kg
13	600 mg/kg or more
18	300 mg/kg or more
19	300 mg/kg or more

Moreover, male ICR mice having a body weight of 23 to 26 g were orally administered with Inventive compound 3. The mice were then observed for 3 days. The MLD was found to be 1,000 mg/kg or more.

The compounds (I) of the present invention may be administered either orally or parenterally. Preparation forms for oral administration may include for example tablets, capsules, powder, granules, and syrup. Preparation forms for parenteral administration include injectable preparations and the like. For the formulation of these preparations, there may be used excipients, disintegrants, binders, lubricants, pigments, diluents and like materials, such as are commonly employed in the art. The excipients may include dextrose, lactose and the like. Starch, carboxymethylcellulose and the like may be used as the disintegrants. Magnesium stearate, talc and the like may be used as the lubricants. The binders may be hydroxypropylcellulose, gelatin, polyvi-

nylpyrrolidone and the like.

The dose may usually be about 1 mg/day to 50 mg/day in the case of an injectable preparation and about 10 mg/day to 500 mg/day in the case of oral administration, both for an adult. The dose may be either increased or decreased depending on the age and other conditions.

The following reference and specific examples are given to further illustrate the present invention, but it is to be noted that the invention is not limited thereto.

Reference Example 1

10 (1) 2-Benzylthiobenzimidazole:

To a solution containing 1.47 g of NaOH dissolved in a mixed solvent consisting of 5 ml of water and 50 ml of ethanol were added 5 g of 2-mercaptopbenzimidazole and 4.2 g of benzyl chloride. The resulting solution was heated under reflux for one hour. The reaction mixture was poured into ice water and crystals precipitated were collected by filtration to give 7.7 g of crude 15 crystals (96%). The crystals were recrystallized from ethanol to obtain 5.9 g of 2-benzylthiobenzimidazole as colorless needles. m.p. 184°C.

(2) 2-Benzylsulfinylbenzimidazole (Comparative compound 1):

In 30 ml of chloroform was dissolved 4.5 g of 2-benzylthiobenzimidazole, followed by gradual 20 addition of 4.6 g of m-chloroperbenzoic acid (purity: 70%) at temperatures below 0°C. The mixture was stirred for 20 minutes and crystals deposited were then collected by filtration. The filtrate was washed successively with a saturated NaHCO_3 solution, sodium thiosulfate and saturated brine and the filtrate thus washed was dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to give 4.3 g of crude crystals. The crystals 25 were recrystallized from ethanol to obtain 2.0 g of 2-benzylsulfinylbenzimidazole as colorless crystals. m.p. 169–170°C.

Example 1

30 (1) 2-(2-Aminobenzylthio)benzimidazole:

In 40 ml of ethanol were dissolved 1.8 g of 2-aminobenzyl chloride hydrochloride and 1.5 g of 30 2-mercaptopbenzimidazole. While shielding light, the resulting solution was stirred at room temperature for 23 hours. Powder precipitated was collected by filtration. After being washed successively with ethanol and ether, the powder was recrystallized from a mixed solvent of methanol and ether to obtain 1.8 g of 2-(2-aminobenzylthio)benzimidazole hydrochloride as 35 colorless granular crystals. m.p. 207°C (decomposed).

(2) 2-(2-Aminobenzylsulfinyl)benzimidazole (Inventive compound 1):

One gram of 2-(2-aminobenzylthio)benzimidazole hydrochloride was dissolved in ice water. The solution was neutralized with 512 mg of sodium bicarbonate, followed by extraction with 40 chloroform. The resulting chloroform solution was washed with saturated brine. After drying the chloroform solution with anhydrous sodium sulfate, the solvent was distilled off under reduced pressure at room temperature. Thereafter, 0.5 g of the thus obtained 2-(2-aminobenzylthio)benzimidazole was dissolved in a mixed solvent which consisted of 30 ml of chloroform and 3 ml of methanol. The resulting solution was chilled to –10°C and added little by little with 0.4 g of 45 m-chloroperbenzoic acid (purity: 70%). The mixture was then stirred at the same temperature for 10 minutes. Light yellowish powder precipitated was collected by filtration. After being washed with ether, the powder was recrystallized from a mixed solvent of methanol and ether to obtain 0.33 g of 2-(2-aminobenzylsulfinyl)benzimidazole as white crystalline powder. m.p. 150°C (decomposed).

50 IR ν_{max} cm^{-1} : 3200, 1440, 1400, 1260, 1035

$^1\text{H-NMR}$ (CDCl_3) δ :

4.40 and 4.64 (each d, 2H, $J=14\text{Hz}$,

55 $\begin{array}{c} \text{O} \\ \uparrow \\ -\text{SCH}_2- \end{array}$, 6.24–7.80 (m, 8H, aromatic protons)

60 Example 2

(1) 2-(2-Methylaminobenzylthio)benzimidazole:

2-Mercaptopbenzimidazole (1.8 g) and 2-methylaminobenzyl chloride hydrochloride (2.5 g) in 10 ml of ethanol were stirred at room temperature for 30 minutes. Ten milliliters of ether was added and crystals precipitated were collected by filtration. The crystals were washed with ether 65 to give 3.5 g of 2-(2-methylaminobenzylthio)benzimidazole hydrochloride (85%). The crystals

5

10

15

20

25

30

35

40

45

50

55

60

65

were suspended in ethyl acetate and then neutralized by addition of a saturated NaHCO_3 solution. After being washed with brine, the organic layer was dried with anhydrous sodium sulfate. After distilling off the solvent under reduced pressure, the residue was recrystallized from acetonitrile to obtain 1.87 g of 2-(2-methylaminobenzylthio)benzimidazole as colorless crystals. m.p. 5 107–108°C.

(2) 2-(2-Methylaminobenzylsulfinyl)benzimidazole
(Inventive compound 2):
2-(2-Methylaminobenzylthio)benzimidazole (1.0 g) was dissolved in 20 ml of chloroform. After 10 chilling the solution to -10°C , 0.87 g of m-chloroperbenzoic acid (purity: 70%) was added little by little. After being stirred at the same temperature for 10 minutes, the mixture was washed successively with a saturated NaHCO_3 solution and saturated brine and then dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and the residue was recrystallized from acetonitrile to obtain 0.43 g of 2-(2-methylaminobenzylsulfinyl)benzimidazole 15 as white crystalline powder. m.p. 122.5–124°C.

IR ν KBr_{max} cm^{-1} : 3220, 1600, 1500, 1435, 1400, 1305, 1265, 1045

$^1\text{H-NMR}$ (CDCl_3) δ : 20 2.52 (s, 3H, $-\text{NCH}_3$), 4.36 and 4.60 (each d, 2H, $J=16\text{Hz}$,

O
↑
25 $-\text{SCH}_2-$), 6.30–7.80 (m, 8H, aromatic protons) 25

Example 3

(1) 2-(2-Dimethylaminobenzylthio)benzimidazole:

2-Mercaptobenzimidazole (4.73 g) was dissolved in 150 ml of ethanol, followed by addition of 30 6.18 g of 2-dimethylaminobenzyl chloride hydrochloride. The mixture was stirred at room temperature for 30 minutes. Crystals precipitated were collected by filtration. A saturated NaHCO_3 solution was added to the crystals, followed by extraction with chloroform. The chloroform layer was washed with saturated brine and then dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and the residue was recrystallized from a mixed solvent 35 of chloroform and acetonitrile to obtain 5.39 g of 2-(2-dimethylaminobenzylthio)benzimidazole as colorless crystals. m.p. 164°C. 35

(2) 2-(2-Dimethylaminobenzylsulfinyl)benzimidazole
(Inventive compound 3):

40 (a) 2-(2-Dimethylaminobenzylthio)benzimidazole (4.8 g) was dissolved in a mixed solvent which consisted of 40 ml of chloroform and 5 ml of methanol. After chilling the solution to 0°C , 3.86 g of m-chloroperbenzoic acid (purity: 70%) was added little by little. Ten minutes later, a saturated NaHCO_3 solution was added to the reaction mixture, followed by extraction with chloroform. The chloroform solution was washed with saturated brine and then dried with 45 anhydrous sodium sulfate. The chloroform was distilled off under reduced pressure and the residue was recrystallized from a mixed solvent of chloroform and ether to obtain 2.97 g of 2-(2-dimethylaminobenzylsulfinyl)benzimidazole as colorless crystals. m.p. 112°C (decomposed). 45

IR ν KBr_{max} cm^{-1} : 3170, 1485, 1435, 1400, 1260, 1040

50 $^1\text{H-NMR}$ (CDCl_3) δ : 2.62 (s, 6H, $>\text{N}(\text{CH}_3)_2$), 4.47 and 4.87 (each d, 2H, $J=14\text{Hz}$,

55 O
↑
55 $-\text{SCH}_2-$), 6.70–7.90 (m, 8H, aromatic protons), 12.16 (br., 1H, $>\text{NH}$)

(b) 2-(2-Dimethylaminobenzylthio)benzimidazole (400 g) was dissolved in methylene chloride 60 (1.06 l)—methanol (1.06 l). Acetic acid (212 ml) was added to the solution and the mixture was stirred until the solid was dissolved completely. After cooling the resulting solution to 2 to 5°C , 182 ml of 35% hydrogen peroxide, 123 ml of water and 8.83 g of ammonium metavanadate were added. The reaction mixture was stirred at 2 to 5°C for 9 hours. The reaction was quenched with a 20% NaHCO_3 solution. The organic layer was separated, washed with an 65 aqueous $\text{Na}_2\text{S}_2\text{O}_3$ solution and with saturated brine and then dried with anhydrous sodium sulfate. 65

The solvent was evaporated under reduced pressure and the residue was recrystallized from acetonitrile to obtain 317 g of 2-(2-dimethylaminobenzylsulfinyl)benzimidazole as colorless crystals.

(c) 2-(2-Dimethylaminobenzylthio)benzimidazole (10 g) was dissolved in a 20% NaOH solution (30 ml) and ethyl acetate (120 ml). After cooling the solution with ice water, a mixture of 70 ml of 12% NaOCl and 30 ml of 20% NaOH was added dropwise at 3 to 5°C over 80 minutes. The reaction mixture was stirred for one hour at the same temperature as just referred to. The reaction was quenched with a 10% Na₂S₂O₃ solution and the organic layer was washed with saturated brine and then dried with anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was recrystallized from acetonitrile to obtain 7.9 g of 2-(2-dimethylaminobenzylsulfinyl)benzimidazole as colorless crystals.

Example 4

(1) 2-(2-Dimethylaminobenzylthio)-5-methoxybenzimidazole:

15 2-Mercapto-5-methoxybenzimidazole (2.70 g) was dissolved in 60 ml of ethanol, followed by addition of 3.09 g of 2-dimethylaminobenzyl chloride hydrochloride. The resulting mixture was stirred at room temperature for 30 minutes. Crystals precipitated were collected by filtration. A saturated NaHCO₃ solution was added to the crystals, followed by extraction with chloroform. The chloroform solution was washed with saturated brine and then dried with anhydrous sodium sulfate. The chloroform was distilled off under reduced pressure to obtain 3.85 g of 2-(2-dimethylaminobenzylthio)-5-methoxybenzimidazole as a colorless oily matter.

20 (2) 2-(2-Dimethylaminobenzylthio)-5-methoxybenzimidazole (2.43 g) was dissolved in a mixed solvent which consisted of 25 ml of chloroform and 2 ml of methanol. After chilling the solution to 0°C, 3.86 g of m-chloroperbenzoic acid (purity: 70%) was added little by little. Ten minutes later, a saturated NaHCO₃ solution was added to the reaction mixture, followed by extraction with chloroform. The chloroform solution was washed with saturated brine and then dried with anhydrous sodium sulfate, followed by removal of the chloroform by distillation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol:50/1) and then recrystallized from a mixed solvent of ether and hexane to obtain 1.50 g of 2-(2-dimethylaminobenzylsulfinyl)-5-methoxybenzimidazole as light yellowish crystals. m.p. 105°C (decomposed).

25 IR ν _{max} KBr cm⁻¹: 3270, 1625, 1485, 1390, 1205, 1175, 1030

30 ¹H-NMR (CDCl₃) δ :

2.63 (s, 6H, -N(CH₃)₂), 3.81 (s, 3H, -OCH₃),
4.48 and 4.85 (each d, 2H, J=15Hz,

35 40 O
↑
-SCH₂-), 6.60-7.80 (m, 7H, aromatic protons),
12.16 (br., 1H, >NH)

40 45 Example 5

(1) 2-(2-Diethylaminobenzylthio)benzimidazole:

45 2-Mercaptobenzimidazole (50.0 g) was suspended in 500 ml of ethanol, followed by addition of 77.9 g of 2-diethylaminobenzyl chloride hydrochloride. The resulting mixture was stirred at room temperature for 30 minutes. Crystals precipitated were collected by filtration and added 50 with a saturated NaHCO₃ solution, followed by extraction with ethyl acetate. The ethyl acetate layer was washed with saturated brine and then dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and the residue was dissolved in ethanol. The resulting solution was treated with activated carbon. The activated carbon was removed by filtration and the ethanol by distillation under reduced pressure. The residue was recrystallized 55 from a mixed solvent of ethyl acetate and hexane to obtain 88.7 g of 2-(2-diethylaminobenzylthio)benzimidazole as light brownish crystalline powder. m.p. 134-135°C.

(2) 2-(2-Diethylaminobenzylsulfinyl)benzimidazole:

60 2-(2-Diethylaminobenzylthio)benzimidazole (84.0 g) was dissolved in a mixed solvent which consisted of 600 ml of methylene chloride and 150 ml of methanol. After chilling the solution to 0°C, 79.8 g of m-chloroperbenzoic acid (purity: 60%) was added little by little. Ten minutes later, a saturated NaHCO₃ solution was added to the reaction mixture, followed by extraction with methylene chloride. The resulting methylene chloride solution was dried with anhydrous sodium sulfate. The methylene chloride was distilled off under reduced pressure and the residue 65 was subjected to silica gel column chromatography (silica gel, 280 g; eluent, acetone:hex-

5

10

15

20

25

30

35

40

45

50

55

60

65

ane=1:2 v/v). The eluate was dissolved in a 1:8 v/v mixed solvent of ethanol and hexane and crystals precipitated were removed by filtration. The filtrate was concentrated under reduced pressure. The residue was recrystallized twice from isopropyl ether to obtain 32.3 g of 2-(2-diethylaminobenzylsulfinyl)benzimidazole as colorless crystals. m.p. 110.5-112°C (decomposed).

5 IR ν KBr max cm⁻¹: 3200, 2980, 1490, 1400, 1270, 1015, 765, 750 5

¹H-NMR (CDCl₃) δ :

10 1.01 (t, 6H, J=7Hz, -CH₂CH₃×2)
3.00 (q, 4H, J=7Hz, -CH₂CH₃×2)
4.46 and 4.97 (each d, 2H, J=13Hz, 10

15 O
↑
-SCH₂-), 6.80-7.90 (m, 8H, aromatic protons),
12.41 (br., 1H, >NH) 15

Example 6

(1) 2-(2-Dimethylaminobenzylthio)-4-methylbenzimidazole:

20 2-Dimethylaminobenzyl chloride hydrochloride (1.26 g) was added to a suspension of 1.0 g of 2-mercaptop-4-methylbenzimidazole in 10 ml of ethanol. The resulting mixture was stirred at room temperature for 2 hours. Crystals precipitated were collected by filtration. After being washed successively with ethanol and ether, the crystals were dissolved in chloroform. The chloroform solution was neutralized with a saturated NaHCO₃ solution, washed with saturated brine and then dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and ether was added to the residue. Crystals precipitated were collected by filtration to obtain 13.8 g of 2-(2-dimethylaminobenzylthio)-4-methylbenzimidazole as white crystalline powder. 20 25

30 ¹H-NMR (CDCl₃) δ :
2.52 (s, 3H), 2.84 (s, 6H), 4.36 (s, 2H),
6.8-7.6 (m, 7H) 30

(2) 2-(2-Dimethylaminobenzylsulfinyl)-4-methylbenzimidazole (Inventive compound 9):

35 2-(2-Dimethylaminobenzylthio)-4-methylbenzimidazole (1.1 g) was dissolved in 15 ml of chloroform, followed by gradual addition of 0.8 g (purity: 80%) of m-CPBA with ice cooling. After being stirred at the same temperature for 10 minutes, the resulting mixture was washed successively with a saturated NaHCO₃ solution and saturated brine and then dried with anhydrous sodium sulfate. The solvent was distilled off under reduced pressure. The residue was recrystallized from acetonitrile to obtain 0.81 g of 2-(2-dimethylaminobenzylsulfinyl)-4-methylbenzimidazole 35 40 45

40 as yellowish crystals. m.p. 112-114°C (decomposed).
IR ν KBr max cm⁻¹: 3200, 1480, 1440, 1420, 1290, 1040, 750

45 ¹H-NMR (CDCl₃) δ :
2.2-2.8 (br, 3H), 2.60 (s, 6H), 4.52 and 4.84
(each d, J=13Hz, 2H), 6.7-7.6 (m, 7H) 45

Example 7

(1) 2-(2-Dimethylamino-6-methylbenzylthio)benzimidazole:

50 2-Dimethylamino-6-methylbenzyl chloride hydrochloride (4.41 g) was dissolved in 40 ml of acetone, followed by addition of 3.64 g of 2-mercaptopbenzimidazole, 10 g of K₂CO₃ and 4 ml of water. The resulting mixture was stirred at room temperature for one hour. Chloroform and water were added to the reaction mixture and the chloroform layer was separated and washed with saturated brine. After drying the chloroform layer with anhydrous sodium sulfate, the 50 55 60 solvents were distilled off under reduced pressure. The residue was crystallized from a mixed solvent of ethanol and hexane and the crystals were collected by filtration to obtain 4.68 g of 2-(2-dimethylamino-6-methylbenzylthio)benzimidazole as light brownish powder. 55

60 ¹H-NMR (CDCl₃) δ :
2.42 (s, 3H), 2.84 (s, 6H), 4.42 (s, 2H),
6.8-7.6 (m, 7H) 60

(2) 2-(2-Dimethylamino-6-methylbenzylsulfinyl)benzimidazole (Inventive compound 10):

65 2-(2-Dimethylamino-6-methylbenzylthio)benzimidazole (2.97 g) was dissolved in a mixed solvent which consisted of 30 ml of chloroform and 3 ml of methanol. With ice cooling 2.18 g of m- 65

CPBA (purity: 80%) was added little by little. The resulting mixture was stirred at the same temperature for 10 minutes, followed by washing first with a saturated NaHCO_3 solution and then with saturated brine, and thereafter dried with anhydrous sodium sulfate, followed by removal of the solvent by distillation under reduced pressure. The residue was recrystallized 5 from a mixed solvent of chloroform and ethanol to obtain 0.75 g of 2-(2-dimethylamino-6-methylbenzylsulfinyl)benzimidazole as white crystalline powder. m.p. 141–142°C (decomposed).

IR ν KBr_{max} cm^{-1} : 3230, 1435, 1400, 1270, 1040, 740

10 $^1\text{H-NMR}$ (CDCl_3) δ :
2.31 (s, 3H), 2.61 (s, 6H), 4.68 and
4.92 (each d, $J=13\text{Hz}$, 2H),
6.8–7.8 (m, 7H)

15 Examples 8–19
In the same manner as in Example 6 or 7, twelve compounds were further prepared, details of which are given in Table 5.

Table 5


					Inventive compound (X=SO)
Example No.	R ₁	R ₂	R ₃	R ₄	Intermediate compound (X=SS)
8 (Inventive compound 5)	C ₁₁ ₃	C ₁₁ ₃	5-COOC ₁ ₃	H	<p>NMR (CDCl₃) δ ppm: 2.80 (s, 6H) 3.00 (s, 3H) 4.36 (s, 2H) 6.9-8.1 (m, 7H)</p> <p>IR ν_{max} cm⁻¹: 3175, 1725, 1490, 1425, 1290, 1080, 1040.</p> <p>NMR (CDCl₃) δ ppm: 2.62 (s, 6H) 3.94 (s, 3H) 4.48 and 4.88 (each d, J=1.3Hz, 2H)</p> <p>m.p. 147-148°C (decomp'd) (acetonitrile)</p> <p>IR ν_{max} cm⁻¹: 3200, 1480, 1440, 1065, 1040, 935, 750.</p>
9 (Inventive compound 6)	C ₁₁ ₃	C ₁₁ ₃	5-CH ₃	H	<p>NMR (CDCl₃) δ ppm: 2.38 (s, 3H) 2.80 (s, 6H) 4.34 (s, 2H) 6.7-7.5 (m, 7H)</p> <p>IR ν_{max} cm⁻¹: 3200, 1480, 1440, 1065, 1040, 935, 750.</p> <p>NMR (CDCl₃) δ ppm: 2.46 (s, 3H) 2.60 (s, 6H) 4.45 and 4.84 (each d, J=1.3Hz, 2H)</p> <p>m.p. 94-95°C (decomp'd) (acetonitrile)</p> <p>IR ν_{max} cm⁻¹: 3200, 1480, 1440, 1065, 1040, 935, 750.</p>
10 (Inventive compound 7)	C ₁₁ ₃	C ₁₁ ₃	5-Cl	H	<p>NMR (CDCl₃) δ ppm: 2.88 (s, 6H) 4.36 (s, 2H) 6.9-7.5 (m, 7H)</p> <p>IR ν_{max} cm⁻¹: 3200, 1490, 1400, 1045, 1040, 760.</p> <p>NMR (CDCl₃) δ ppm: 2.66 (s, 6H) 4.49 and 4.83 (each d, J=1.3Hz, 2H)</p> <p>m.p. 130.5-131.5°C (decomp'd)</p> <p>IR ν_{max} cm⁻¹: 3200, 1490, 1400, 1045, 1040, 760.</p>

Table 5 (cont'd)

Example No.	R_1	R_2	R_3	R_4	Intermediate compound ($X=S$)	Inventive compound ($X=Se$)
11 (Inventive compound 8)	CH_3	CH_3	$5-CF_3$	H	NMR ($CDCl_3$) δ ppm: 2.92 (s, 6II) 4.38 (s, 2II) 7.0-7.7 (m, 7II)	m.p. 148°C (decomp'd) (acetonitrile) NMR ($CDCl_3$) δ ppm: 2.66 (s, 6II) 4.50 and 4.68 (each d, $J=13$ Hz, 2II) 6.8-8.1 (m, 7II)
12	CH_3	CH_3	$5-NH_2$	H	NMR ($CDCl_3$) δ ppm: 2.06 (s, 6II) 4.34 (s, 2II) 6.4-7.5 (m, 7II)	m.p. 146-148°C (decomp'd) (ethanol-ether) IR ν_{KBr} cm $^{-1}$: 3200, 1620, 1490, 1400, 1205, 1050, 760 NMR (CD_3OD) δ ppm: 2.57 (s, 6II) 4.54 and 4.79 (each d, $J=13$ Hz, 2II) 6.6-7.4 (m, 7II)
13 (Inventive compound 11)	CH_3	CH_3	H	4-Cl	NMR ($CDCl_3$) δ ppm: 2.80 (s, 6II) 4.40 (s, 2II) 6.8-7.6 (m, 7II)	m.p. 139-140°C (decomp'd) (acetonitrile) IR ν_{KBr} cm $^{-1}$: 1585, 1425, 1400, 1260, 1060, 950, 740 NMR ($CDCl_3$) δ ppm: 2.58 (s, 6II) 4.42 and 4.78 (each d, $J=13$ Hz, 2II) 6.7-7.8 (m, 7II)
14 (Inventive compound 12)	CH_3	CH_3	H	$5-OCH_3$	NMR ($CDCl_3$) δ ppm: 2.04 (s, 6II) 3.72 (s, 3II) 4.32 (s, 2II) 6.6-7.6 (m, 7II)	m.p. 115-116.5°C (decomp'd) (ethyl acetate) IR ν_{KBr} cm $^{-1}$: 3200, 1495, 1400, 1280, 1245, 1150, 1020 NMR ($CDCl_3$) δ ppm: 2.60 (s, 6II) 3.50 (s, 3II) 4.47 and 4.87 (each d, $J=13$ Hz, 2II) 6.6-7.8 (m, 7II)

Table 5 (cont'd)

Example No.	R ₁	R ₂	R ₃	R ₄	Intermediate compound (X=S)	Inventive compound (X=SO)	
15 (Inventive compound 13)	CII ₃	CII ₃	H	S-Me	NMR (CDCl ₃) δ ppm: 2.24 (s, 3II) 2.82 (s, 6II) 4.30 (s, 2II) 6.8-7.5 (m, 7II)	m.p. 141.5-142.5°C (decomp'd) (ethanol-heptane) IR ν KBr cm ⁻¹ : 3220, 1600, 1410, 1270, 1045, 820, 740 NMR (CDCl ₃) δ ppm: 2.09 (s, 3II) 2.62 (s, 6II) 4.45 and 4.84 (each d, J=13Hz, 2II) 6.9-7.8 (m, 7II)	
16	CII ₃	CII ₃	H	3-Me	NMR (CDCl ₃) δ ppm: 2.30 (s, 3II) 2.84 (s, 6II) 4.52 (s, 2II) 6.8-7.7 (m, 7II)	m.p. 155-156°C (decomp'd) (acetone-hexane) IR ν KBr cm ⁻¹ : 3160, 1430, 1400, 1260, 1075, 1015, 860, 830 NMR (CDCl ₃) δ ppm: 2.35 (s, 3II) 2.86 (s, 6II) 4.38 and 4.85 (each d, J=13Hz, 2II) 6.8-8.0 (m, 7II)	
17	CII ₃	CII ₃	H	4-F		NMR (CDCl ₃) δ ppm: 2.76 (s, 6II) 4.30 (s, 2II) 6.5-7.6 (m, 7II)	m.p. 118-119°C (decomp'd) (methylenechloride-acetonitrile) IR ν KBr cm ⁻¹ : 3170, 1605, 1580, 1490, 1210, 1035, 980, 760 NMR (CDCl ₃) δ ppm: 2.60 (s, 6II) 4.44 and 4.80 (each d, J=13Hz, 2II) 6.4-7.7 (m, 7II)

Table 5 (cont'd)

Example No.	R ₁	R ₂	R ₃	R ₄	Intermediate compound (X=S)	Inventive compound (X=SO)
18	CH ₃	CH ₃	5-OCH ₃	6-CH ₃	NMR (CDCl ₃) 6 ppm: 2.44 (s, 3H) 2.90 (s, 6H) 3.00 (s, 3H) 4.40 (s, 2H) 6.6-7.4 (m, 6H)	in.p. 143-146°C (decomp'd) (acetone-ether) IR ν _{max} cm ⁻¹ : 3220, 1440, 1190, 1140, 1035, 790 NMR (CDCl ₃) 6 ppm: 2.34 (s, 3H) 2.63 (s, 6H) 3.84 (s, 3H) 4.38 and 4.86 (each d, J=1.3Hz, 2H) 6.8-7.7 (m, 6H)
19	CH ₃	CH ₃	5-Cl	5-OCH ₃	NMR (CDCl ₃) 6 ppm: 2.80 (s, 6H) 3.74 (s, 3H) 4.20 (s, 2H) 6.6-7.5 (m, 6H)	in.p. 161-162°C (decomp'd) (acetone) IR ν _{max} cm ⁻¹ : 3210, 1495, 1395, 1285, 1250, 1040, 1025, 810 NMR (CDCl ₃) 6 ppm: 2.61 (s, 6H) 3.58 (s, 3H) 4.40 and 4.82 (each d, J=1.3Hz, 2H) 6.6-7.8 (m, 6H)

Example 20

(2) 2-(2-Piperidinobenzylthio)benzimidazole:

To a solution of 1.42 g of 2-piperidinobenzyl chloride hydrochloride in 35 ml of ethanol were added 0.87 g of 2-mercaptopbenzimidazole and 0.5 g of NaOH. The mixture was stirred at room temperature for 5 hours. The solvent was distilled off under reduced pressure. Water was added to the residue, followed by extraction with ethyl acetate. The ethyl acetate solution was washed successively with a 10% NaOH solution and saturated brine. After drying the resulting solution with anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was washed with ether to obtain 1.0 g of 2-(2-piperidinobenzylthio)benzimidazole as yellow powder. m.p. 165°C.

NMR (CDCl₃) δ :

1.4–2.1 (m, 6H), 2.8–3.1 (m, 4H), 4.34 (s, 2H), 6.9–7.6 (m, 8H)

15

(2) 2-(2-Piperidinobenzylsulfinyl)benzimidazole (Inventive compound 14):

2-(2-Piperidinobenzylthio)benzimidazole (0.70 g) was dissolved in a mixed solvent which consisted of 50 ml of chloroform and 2 ml of methanol, followed by gradual addition of 1.3 g of m-CPBA (purity: 80%) with ice cooling. The resulting mixture was stirred at the same temperature for 10 minutes. Thereafter, the mixture was washed successively with a saturated NaHCO₃ solution and saturated brine and then dried with anhydrous sodium sulfate. The solvents were distilled off under reduced pressure and the residue was recrystallized from ether to obtain 0.45 g of 2-(2-piperidinobenzylsulfinyl)benzimidazole as white powder. m.p. 158°C (decomposed).

25 IR ν _{max}^{KBr} cm⁻¹: 3160, 1435, 1325, 1215, 1030, 920, 740

¹H-NMR (DMSO-d₆) δ :

1.3–1.8 (m, 6H), 2.6–2.8 (m, 4H), 4.41–4.74 (each d, J=12Hz, 2H), 6.8–7.8 (m, 8H)

30

Examples 21–26

In the same manner as in Example 20, six compounds were further prepared, details of which are given in Table 6.

5

10

15

20

25

30

Table 6

Example No.	R_1	R_2	R_3	R_4	Intermediate compound ($\text{X}=\text{S}$)	Inventive compound ($\text{X}=\text{SO}$)
21 (Inventive compound 15)		II	II	II	NMR (CDCl_3) δ ppm: 0.9-2.1 (m, 10H) 3.0-3.4 (br, 1H) 4.48 (s, 2H) 6.4-7.6 (m, 8H)	m.p. 89-92°C (decomp'd) (acetonitrile) IR ν_{KBr} cm^{-1} : 2940, 1605, 1510, 1430, 1310, 1270, 1050, 750 NMR (CDCl_3) δ ppm: 0.7-2.1 (m, 10H) 2.9-3.3 (m, 1H) 4.35 and 4.64 (each d, $\text{J}=14\text{Hz}$, 2H) 6.3-7.9 (m, 8H)
22 (Inventive compound 16)		II	II	II	NMR (CDCl_3) δ ppm: 4.48 (s, 2H) 6.6-7.5 (m, 13H)	m.p. 89-92°C (decomp'd) (chloroform-ether) IR ν_{KBr} cm^{-1} : 3360, 1600, 1495, 1410, 1305, 1050, 750 NMR (CDCl_3) δ ppm: 4.47 and 4.78 (each d, $\text{J}=14\text{Hz}$, 2H) 6.5-8.0 (m, 13H)
23 (Inventive compound 17)		ClI ₃	II	II	NMR (CDCl_3) δ ppm: 3.18 (s, 3H) 4.40 (s, 2H) 6.4-7.6 (m, 13H)	m.p. 168-169°C (decomp'd) (chloroform-acetonitrile) IR ν_{KBr} cm^{-1} : 3050, 1590, 1485, 1400, 1260, 1055, 740 NMR (CDCl_3) δ ppm: 3.18 (s, 3H) 4.32 and 4.62 (each d, $\text{J}=13\text{Hz}$, 2H) 6.3-7.8 (m, 13H)

Table 6 (cont'd)

Example No.	R ₁	R ₂	R ₃	R ₄	Intermediate compound (X=S)	Inventive compound (X=SO)
24 (Inventive compound 18)	-CH ₂ - 	ClI ₃	II	II	NMR (CDCl ₃) δ ppm: 2.66 (s, 3II) 4.04 (s, 2II) 4.56 (s, 2II) 6.9-7.5 (m, 13II)	m.p. 137°C (decomp'd) (acetonitrile) IR ν _{max} cm ⁻¹ : 3170, 1440, 1400, 1260, 1025, 940, NMR (CDCl ₃) δ ppm: 2.52 (s, 3II) 4.00 (s, 2II) 4.52 and 4.92 (each d, J=12Hz, 2II) 6.7-7.9 (m, 13II)
25	-(CH ₂) ₅ ClI ₃	ClI ₃	II	II	NMR (CDCl ₃) δ ppm: 0.90 (d, J=7Hz, 6II) 1.0-2.2 (m, 1II) 2.69 (d, J=8Hz, 2II) 2.80 (s, 3II) 4.40 (s, 2II) 6.9-7.8 (m, 8II)	m.p. 121°C (decomp'd) (chloroform-hexane) NMR (CDCl ₃) δ ppm: 0.92 (d, J=7Hz, 6II) 1.5-2.0 (m, 1II) 2.62 (d, J=8Hz, 2II) 2.64 (s, 3II) 4.52 and 4.90 (each d, J=14Hz, 2II) 6.8-7.9 (m, 8II)
26 (Inventive compound 19)	-CH ₂ ClI(ClI ₃) ₂	ClI ₃	II	II	NMR (CDCl ₃) δ ppm: 0.6-2.0 (m, 1II) 2.7-3.1 (m, 2II) 2.80 (s, 3II) 4.42 (s, 2II) 6.8-7.7 (m, 8II)	m.p. 90-92.5°C (decomp'd) (chloroform-hexane) NMR (CDCl ₃) δ ppm: 0.7-1.7 (m, 1II) 2.64 (s, 3II) 2.7-3.0 (m, 2II) 4.48 and 4.89 (each d, J=12Hz, 2II) 6.7-8.0 (m, 8II)

The following examples illustrate the use of the benzimidazole components of the invention in antiulcer agents in various forms, the effective component in each case being a compound in accordance with the invention.

5 5 Example 27

Preparation Example (Tablets):

Each tablet (220 mg) contained the following components:

Effective component	50 mg	
10 Lactose	103 mg	10
Starch	50 mg	
Magnesium stearate	2 mg	
Hydroxypropylcellulose	15 mg	

15 15 Example 28

Preparation Example (Capsules):

Each hard gelatin capsule (350 mg) contained the following components:

Effective component	40 mg	
20 Lactose	200 mg	20
Starch	70 mg	
Polyvinylpyrrolidone	5 mg	
Crystalline cellulose	35 mg	

25 25 Example 29

Preparation Example (Granules):

Each granule (1 g) contained the following components:

Effective component	200 mg	
30 Lactose	450 mg	30
Corn starch	300 mg	
Hydroxypropylcellulose	50 mg	

Example 30

35 35 Preparation Example (Enteric Coated Tablets):

Each enteric coated tablet contained the components of Example 27.

The terms "lower alkyl", "lower alkoxy" and "lower alkoxy carbonyl" as used herein in the definition of groups R_3 and R_4 of Formula (I), are intended to mean alkyl and alkoxy groups having 1 to 5 carbon atoms, and alkoxy carbonyl groups in which the alkoxy moiety has 1 to 5 carbon atoms.

40 40

CLAIMS

1. A benzimidazole derivative represented by the formula (I),




where R_1 is a hydrogen atom, or an alkyl group of 1 to 8 carbon atoms, or a cycloalkyl, phenyl, or aralkyl group; R_2 is a hydrogen atom, or an alkyl group of 1 to 8 carbon atoms; or R_1 and R_2 form a ring together with the adjacent nitrogen atom; and R_3 and R_4 are in each case a hydrogen or halogen atom, or a trifluoromethyl, lower alkyl, lower alkoxy, lower alkoxy carbonyl, or amino group, and may be the same or different.

55 55 2. A benzimidazole derivative as claimed in Claim 1, substantially as hereinbefore described with reference to any of Examples 1 to 26.

3. A process for preparing a benzimidazole derivative as claimed in Claim 1, which comprises 60 reacting a 2-mercaptopbenzimidazole represented by the formula (II),




where R_3 is as defined in Claim 1, with a 2-aminobenzyl compound represented by the formula (III),



10 where R_1 , R_2 and R_4 are as defined in Claim 1 and X is a reactive group, thereby forming a

5

10



15

20 where R_1 , R_2 , R_3 and R_4 are as defined in Claim 1, and thereafter oxidizing the compound of the formula (IV).

20

4. A process for preparing a benzimidazole derivative as claimed in Claim 1, substantially as hereinbefore described with reference to any of Examples 1 to 26.

5. An antiulcer agent comprising as an effective component a benzimidazole derivative as claimed in Claim 1.

25 6. An antiulcer agent as claimed in Claim 5, substantially as described with reference to any of Examples 27 to 30.

25